SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Essential medicines for cancer: WHO recommendations and national priorities
6 references·0 citing·26 second hop
Essential medicines for cancer: WHO recommendations and national priorities (2016)Essential medicines for cancer: WHO recom…In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs (2015)In Support of a Patient-Drive…American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)American Society of Clinical …A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)A standardised, generic, vali…Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries (2014)Evidence-informed frameworks …The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)The price of drugs for chroni…American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology (2012)American Society of Clinical …Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Pricing in the Market for Anticancer Drugs (2015)National trends in prescription drug expenditures and projections for 2016 (2016)The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology (2016)The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017)Medical Bankruptcy in the United States, 2007: Results of a National Study (2009)The Price of Inequality (2013)Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)GRADE guidelines: 3. Rating the quality of evidence (2011)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Net Health Benefits (1998)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Essential medicines for universal health coverage (2016)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)Projections of Global Mortality and Burden of Disease from 2002 to 2030 (2006)World Development Report 2012: Gender equality and development (2012)Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes (2015)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)Leveraging national and global political determinants of health to promote equity in cancer care (2023)The State of Cancer Care in America, 2014: A Report by the American Society of Clinical Oncology (2014)Measuring the Value of Prescription Drugs (2015)
this work references cited by second hop

References

  • 2015American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options916 cited
  • 2015A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)817 cited
  • 2012American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology650 cited
  • 2013The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts592 cited
  • 2014Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries163 cited
  • 2015In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs145 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work